Skip to nav Skip to content

Clinical Trial Search

294 Clinical Trials Found

Clinical Trial 20733

Disease Site: Myeloid and Monocytic Leukemia
PI: Vargas Madueno, Fernando

Clinical Trial 21923

A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Disease Site: Liver
PI: Kim, Richard

Clinical Trial 21971

Phase I Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients with Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)
Disease Site: Lung
PI: Creelan, Benjamin

Clinical Trial 22263

A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or B-cell Non-Hodgkin Lymphoma
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Soft Tissue
PI: Pinilla-Ibarz, Javier

Clinical Trial 22319

A Phase 1B/2 Open-Label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy with Activated, Gene Modified Allogeneic or Autologous gamma delta T Cells (DELTEX) in Combination with Maintenance Temozolomide in Subjects with Recurrent or Newly Diagnosed Glioblastoma
Disease Site: Brain and Nervous System
PI: Liu, James

Clinical Trial 22331

A Phase I trial to assess safety, tolerability, pharmacokinetics, radiation dosimetry, and positron emission tomography (PET) imaging properties of 89Zr-labelled hNd2 (NMK89) in patients with pancreatic cancer histologically positive for MUC5AC
Disease Site: Pancreas
PI: Gage, Kenneth

Clinical Trial 22349

Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
Disease Site: Urinary Bladder
PI: Li, Roger

Clinical Trial 22369

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
Disease Site: Breast, Esophagus, Kidney, Pancreas, Stomach
PI: Biachi de Castria, Tiago

Clinical Trial 22486

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Disease Site: Larynx, Lip, Oral Cavity and Pharynx, Head & Neck, Mouth, lip, nasal cavity
PI: Chung, Christine

Clinical Trial 22534

Disease Site: Multiple Myeloma
PI: Shain, Kenneth

Clinical Trial 23347

Disease Site: Breast
PI: Washington, Iman

Clinical Trial 21690

A Phase 1b, Single Arm Study of CG0070 after Transurethral Resection in Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Disease Site: Urinary Bladder, Other Urinary
PI: Li, Roger